- Conditions
- Neoplasm Metastasis
- Interventions
- methotrexate, Cyclosporin
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 10 Years to 80 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma
- Interventions
- rituximab, methotrexate, temozolomide 100 mg/m^2, temozolomide 150 mg/m^2, temozolomide 200 mg/m^2, radiation therapy, post-radiation therapy temozolomide
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 26
- States / cities
- Jacksonville, Florida • Jacksonville Beach, Florida • Orange Park, Florida + 17 more
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Interventions
- Total-Body Irradiation, Thiotepa, Fludarabine, Tacrolimus, Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Methotrexate, Cyclophosphamide, Peripheral Blood Stem Cell, Cyclosporine, Sirolimus, Busulfan, Bone Marrow Aspiration and Biopsy, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection
- Radiation · Drug · Biological + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 1 Year to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- Osteosarcoma, Malignant Fibrous Histiocytoma (MFH) of Bone
- Interventions
- Bevacizumab, Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, etoposide, Surgery, Radiotherapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 5
- States / cities
- San Diego, California • Baltimore, Maryland • Bethesda, Maryland + 2 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Humax-CD4, Placebo
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 50
- States / cities
- Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 25 more
- Conditions
- Inflammation, Vasculitis, Wegener's Granulomatosis
- Interventions
- prednisone and methotrexate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1990 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
- Interventions
- Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX), Placebo SC, Placebo IV
- Drug
- Lead sponsor
- Janssen Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more
- Conditions
- Gout
- Interventions
- Pegloticase, Methotrexate
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 63 more
- Conditions
- Lymphoblastic Lymphoma
- Interventions
- Vincristine, Radiation Therapy, Daunomycin, L-Asparaginase, Cytarabine, Methotrexate, Mercaptopurine, Etoposide, Cyclophosphamide, Prednisone, Dexamethasone
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2004
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- AIDS-Related-Primary Central Nervous System Lymphoma
- Interventions
- Methotrexate, Rituximab, Leucovorin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Arthritis, Juvenile
- Interventions
- Golimumab, Methotrexate
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 14
- States / cities
- San Diego, California • Chicago, Illinois • Boston, Massachusetts + 11 more
- Conditions
- Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
- Interventions
- DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Rheumatoid Arthritis
- Interventions
- P38 Inhibitor (4) 150mg, P38 Inhibitor (4) 25mg, P38 Inhibitor (4) 300mg, P38 Inhibitor (4) 50mg, P38 Inhibitor (4) 75mg, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 42 more
- Conditions
- Early Rheumatoid Arthritis
- Interventions
- Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
- Biological · Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2012
- U.S. locations
- 31
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
- Conditions
- Inflammatory Bowel Disease (IBD)
- Interventions
- Semen & Data Collection
- Procedure
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Burkitt's Lymphoma, Burkitt'S-like Lymphoma
- Interventions
- Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, G-CSF, Cytarabine, Methotrexate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 4 more
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoma, Lymphoblastic
- Interventions
- Etoposide, cytarabine, vincristine, dexamethasone, methotrexate, teniposide, PEG-asparaginase, mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine, L-asparaginase, erwinia asparaginase, chemotherapy, intrathecal chemotherapy, steroid therapy, Hematopoietic Stem Cell Transplant, Natural Killer (NK) Cell Transplant
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 2
- States / cities
- San Diego, California • Memphis, Tennessee
- Conditions
- Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia
- Interventions
- Blinatumomab, Oncaspar, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Mercaptopurine, Methotrexate, Vincristine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 51 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphoblastic Leukemia, Lymphoblastic Lymphoma
- Interventions
- Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Methotrexate, Doxorubicin, Thioguanine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- radiation therapy, cyclophosphamide, anti-thymocyte globulin, tacrolimus, methotrexate, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis
- Radiation · Drug · Biological + 2 more
- Lead sponsor
- Sumithira Vasu
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Rheumatoid Arthritis
- Interventions
- Secukinmab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 13
- States / cities
- Mesa, Arizona • Peoria, Arizona • Little Rock, Arkansas + 10 more